Trusted Resources: Evidence & Education
Scientific literature and patient education texts
TEPEZZA (teprotumumab-trbw)- Frequently Asked Questions
source: Horizon Therapeutics
year: N/A
summary/abstract:1. What is TEPEZZA?
TEPEZZA is the first and only medicine FDA-approved to treat Thyroid Eye Disease. Unlike other medicines you and your doctor may have tried, TEPEZZA treats the cause of Thyroid Eye Disease. When you have Thyroid Eye disease, a switch behind your eye, called a receptor, is turned on that causes redness and swelling. This can also make your eyes bulge. TEPEZZA is the only medicine that blocks this receptor to treat Thyroid Eye Disease at its source.
2. What is Thyroid Eye Disease?
Thyroid Eye Disease is a vision-threatening autoimmune disease that often occurs in people living with Graves’ disease; however, it is a different disease that must be managed separately. Common symptoms of Thyroid Eye Disease include double vision, bulging eyes, dry eyes, eye pain, eyelid redness and swelling, teary eyes, light sensitivity and vision changes.
3. How do I know if TEPEZZA is right for me?
If you are experiencing symptoms of Thyroid Eye Disease or have been diagnosed with the disease, you should speak with your physician about potential treatment options.
More from Teprotumumab News:
FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)
Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease
Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED
FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED
More from Teprotumumab Research:
Teprotumumab for the Treatment of Active Thyroid Eye Disease
(Authors: Raymond S. Douglas, George J. Kahaly et. al.)
Teprotumumab in the Treatment of Active TED: A Focus on Proptosis
(Author: Raymond S. Douglas)
read more
Related Content
-
Management of Graves’ Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
-
Preoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...
-
Measuring Health-Related Quality of Life in Thyroid Eye DiseaseHealth-related quality of life (HQOL) is...
-
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseasePrior clinical trials of TEPEZZA(TM) hav...
-
TED Pathogenesis: A Complex Story of Disordered Signalinghttps://www.tedimpact.com/thyroid-eye-di...
-
Vikram David Durairaj, MD, FACSDr. Vikram David Durairaj is a board cer...
-
Evaluation of Depression and Anxiety in a Diverse Population With Thyroid Eye Disease Using the Nationwide NIH All o...Purpose: To evaluate the prevalence o...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.